Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary

Rheumatology International
Original Article
Thursday, October 01, 2009
María Teresa Saldaña1, 2 , Ana Navarro3, Concepción Pérez4, Xavier Masramón5 and Javier Rejas6

(1) Centro de Salud de Raíces, Av. del Campón 67, 33400 Castrillón (Asturias), Spain
(2) Raíces Primary Care Center, Castrillón, Asturias, Spain
(3) Puerta del Ángel Primary Care Center, Madrid, Spain
(4) Pain Clinic, De la Princesa Hospital, Madrid, Spain
(5) Department of Statistics, European Biometrics Institute, Barcelona, Spain
(6) Health Outcomes Research Department, Medical Unit, Pfizer Spain, Alcobendas, Spain

Received: 28 October 2008 Accepted: 5 August 2009 Published online: 2 October 2009

Abstract The objective of this study was to evaluate the effect of pregabalin in painful cervical or lumbosacral radiculopathy treated in Primary Care settings under routine clinical practice. An observational, prospective 12-week secondary analysis was carried-out. Male and female above 18 years, naïve to PGB, with refractory chronic pain secondary to cervical/lumbosacral radiculopathy were enrolled. SF-MPQ, Sheehan Disability Inventory, MOS Sleep Scale, Hospital Anxiety and Depression Scale and the EQ-5D were administered. A total of 490 (34%) patients were prescribed PGB-monotherapy, 702 (48%) received PGB add-on, and 159 (11%) were administered non-PGB drugs. After 12 weeks, significant improvements in pain, associated symptoms of anxiety, depression and sleep disturbances, general health; and level of disability were observed in the three groups, being significantly greater in PGB groups. In routine medical practice, monotherapy or add-on pregabalin is associated with substantial pain alleviation and associated symptoms improvements in painful cervical or lumbosacral radiculopathy.